Sivan Harel
Overview
Explore the profile of Sivan Harel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
994
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kosloski M, Guttman-Yassky E, Cork M, Worm M, Nahm D, Zhu X, et al.
Clin Transl Sci
. 2024 Jul;
17(8):e13874.
PMID: 39077906
Interleukin-33 (IL-33) is a proinflammatory alarmin cytokine released by damaged epithelial tissue cells that initiates and amplifies both type 1 and type 2 inflammatory cascades. A role for IL-33 in...
2.
Gayvert K, Desrosiers M, Laidlaw T, Mannent L, Patel K, Horowitz J, et al.
J Allergy Clin Immunol
. 2024 Jun;
154(3):619-630.
PMID: 38880251
Background: There is evidence of pathophysiologic diversity in chronic rhinosinusitis with nasal polyps (CRSwNP), but data characterizing the molecular endotypes of CRSwNP and their association with treatment are lacking. Objective:...
3.
Bachert C, Gevaert P, Lipworth B, Mustafa S, Lane A, Mullol J, et al.
Allergy
. 2024 Jun;
79(10):2858-2861.
PMID: 38850227
No abstract available.
4.
Wipperman M, Gayvert K, Atanasio A, Wang C, Corren J, Covarrubias A, et al.
Allergy
. 2024 Jan;
79(4):894-907.
PMID: 38279910
Background: Nasal epithelial cells are important regulators of barrier function and immune signaling; however, in allergic rhinitis (AR) these functions can be disrupted by inflammatory mediators. We aimed to better...
5.
Faiz A, Mahbub R, Boedijono F, Tomassen M, Kooistra W, Timens W, et al.
Am J Respir Crit Care Med
. 2023 Sep;
208(10):1075-1087.
PMID: 37708400
IL-33 is a proinflammatory cytokine thought to play a role in the pathogenesis of asthma and chronic obstructive pulmonary disease (COPD). A recent clinical trial using an anti-IL-33 antibody showed...
6.
Bachert C, Laidlaw T, Cho S, Mullol J, Swanson B, Naimi S, et al.
Ann Otol Rhinol Laryngol
. 2023 Jun;
132(12):1649-1661.
PMID: 37322842
Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and non-steroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD) are frequent coexisting conditions and share type 2 inflammatory pathophysiology, with interleukin (IL)-4 and IL-13...
7.
Pavord I, Deniz Y, Corren J, Casale T, FitzGerald J, Izuhara K, et al.
J Allergy Clin Immunol Pract
. 2022 Dec;
11(4):1213-1220.e2.
PMID: 36535524
Background: FeNO may have a role as both a prognostic and predictive biomarker in combination with eosinophils for assessing responsiveness to some biological therapies. Objective: We evaluated the value of...
8.
Bachert C, Corren J, Lee S, Zhang H, Harel S, Cunoosamy D, et al.
Int Forum Allergy Rhinol
. 2021 Dec;
12(9):1191-1195.
PMID: 34970860
No abstract available.
9.
Kosloski M, Kalliolias G, Xu C, Harel S, Lai C, Zheng W, et al.
Clin Transl Sci
. 2021 Sep;
15(2):384-395.
PMID: 34523807
Itepekimab is a monoclonal antibody that targets interleukin (IL-33) and has been shown to reduce airway inflammation and associated tissue damage in preclinical studies. We assessed the safety, tolerability, pharmacokinetics...
10.
Busse W, Wenzel S, Casale T, FitzGerald J, Rice M, Daizadeh N, et al.
Lancet Respir Med
. 2021 Jun;
9(10):1165-1173.
PMID: 34181876
Background: Fractional exhaled nitric oxide (FeNO) has potential as a prognostic biomarker in asthma, but its prognostic value among other recognised indicators is unclear. We assessed the added prognostic value...